Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The study is aimed at Evaluation of the potential protective effect of Vitamin D in
doxorubucin- induced toxicity in breast cancer patients.
Proposal Steps:
1. 100 Patients recruited from Alexandria Main University Hospital (AMUH), Oncology Unit
are randomly assigned in to two groups:
- Control group (n=50) the patient will receive AC regimen (Doxorubucin &
cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)
- Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin
D (Bon One 0.5 microgram®) once daily.
2. Echocardiography (Echo) will be done at base line and at the end of the treatment.
3. Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end
of the study.
Phase:
Phase 2
Details
Lead Sponsor:
Damanhour University
Treatments:
Alfacalcidol Doxorubicin Ergocalciferols Hydroxycholecalciferols Vitamin D Vitamins